GlassScriptPhysician profile
Michael N Mandese
NPI 1720079577
$1,986.14
in general payments reported to CMS, 2019-2025
20 companies · $317 in 2025
The $317 reported for 2025 was more than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $204 · 2020: $246 · 2021: $208 · 2022: $245 · 2023: $107 · 2024: $658 · 2025: $317.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $975 · Entertainment: $107.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $975.17 |
| Entertainment | $107.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $293.05 | 2024-2025 | Tepezza |
| Alcon Vision LLC | $289.08 | 2019-2023 | Total30 |
| Bausch & Lomb Americas INC. | $266.82 | 2024-2025 | Xiidra, Miebo, Infuse Multifocal |
| Glaukos Corporation | $216.36 | 2020-2024 | Ce-Marked Kxla System |
| Sun Pharmaceutical Industries INC. | $122.31 | 2020 | |
| Optos, INC. | $107.37 | 2024 | Panoramic Ophthalmoscope, Oct Ophthalmoscope, Nfc-700 |
| Shire North American Group INC | $103.05 | 2019 | |
| Visionix USA, INC | $90.91 | 2022 | |
| Dompe US, INC. | $83.55 | 2025 | Oxervate |
| Kala Pharmaceuticals, INC. | $80.56 | 2021-2022 | |
| Coopervision INC. | $64.89 | 2019 | |
| Abbvie INC. | $63.48 | 2022-2023 | |
| Horizon Therapeutics Plc | $49.73 | 2022 | |
| Oyster Point Pharma, INC. | $36.86 | 2022-2025 | Ryzumvi, Tyrvaya |
| Tarsus Pharmaceuticals, INC. | $29.84 | 2025 | Xdemvy |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $25.14 | 2024 | Izervay |
| Harrow Eye, LLC | $22.51 | 2025 | Vevye |
| Allergan, INC. | $16.93 | 2021 | |
| Novartis Pharmaceuticals Corporation | $16.59 | 2019 | |
| Lkc Technologies, INC. | $7.11 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Mandese listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.